Table 3.
Deferasirox dosing in patients with myelodysplastic syndromes
| Dosing | Chelation-naïve (n = 123) | Prior chelation (n = 44) |
|---|---|---|
| Mean starting dose, mg/kg/d | 15.7 | 18.7 |
| Patients starting on 20 to <30 mg/kg/d, n (%) | 59 (48.3) | 22 (50.0) |
| Median daily deferasirox dose over the course of the studies, mg/kg/d (range) | 20 (2.0–30.3) | 20 (4.7–35.0) |
| Median time on deferasirox treatment, d (range) | 357 (2–511) | 317 (16–463) |
| Dose adjustments for all starting doses1, n (%) | ||
| Unchanged | 59 (48.0) | 22 (50.0) |
| Increased | 8 (6.5) | 1 (2.3) |
| Reduced | 5 (4.1) | 5 (11.4) |
| Missing data | 50 (40.7) | 16 (36.4) |
| One or two dose interruptions | 14 (11.4) | 7 (15.9) |
1
Baseline compared with final visit.